

Supplementary Table 1. A summary of the clinical course of patients with relapsed APL in arsenic-based consolidation without HSCT group (N=19).

Patient No.	Sex	Age (yr)	Sanz risk (initial)	CR1 duration (mo)	Reinduction treatment	Treatment response	Consolidation treatment	Maintenance treatment ^{a)}	CR2 duration (mo)	2 nd relapse	3 rd relapse	Clinical outcome
1	F	45	Low	30.2	ATO	CHR2	ATO 10 days 2 cycles	None	3.4	No	No	Expired due to V. fib cardiac arrest during 2 nd consolidation
2	F	36	Intermediate	33.2	ATO+ATRA	CMR2	ATO 28 days 1 cycle	8 cycles	18.1	No	No	Alive without 2 nd relapse
3	F	53	High	24.5	ATO	CCR2	ATO 28 days 2 cycles ATO 10 days 4 cycles	4 cycles	13.9	Yes	Yes	Expired due to disease progression after 3 rd relapse
4	M	18	High	14.3	ATO	CCR2	ATO 28 days 2 cycles	8 cycles	153.3	No	No	Alive without 2 nd relapse
5	F	41	High	23.8	ATO	CMR2	ATO 28 days 1 cycle ATO 14 days 2 cycles	8 cycles	145.7	No	No	Alive without 2 nd relapse
6	M	26	Intermediate	17.6	ATO+ATRA	CMR2	ATO 28 days 1 cycle ATO 10 days 5 cycles	8 cycles	87.6	No	No	Alive without 2 nd relapse
7	F	31	Intermediate	16.7	ATO	CMR2	ATO 28 days 1 cycle ATO 10 days 5 cycles	8 cycles	141.5	No	No	Alive without 2 nd relapse
8	F	51	High	25.8	ATO	CMR2	ATO 10 days 6 cycles	4 cycles	19.2	Yes ^{b)}	No	Expired after salvage allo-HSCT due to CMV pneumonia
9	F	48	High	36.7	ATO	CMR2	ATO 25 days 2 cycles	8 cycles	24.9	No	No	Alive without 2 nd relapse
10	M	44	High	18.0	ATO	CMR2	ATO 25 days 2 cycles	8 cycles	72.3	No	No	Alive without 2 nd relapse
11	F	42	High	33.4	ATO	CMR2	ATO 25 days 2 cycles	8 cycles	48.2	Yes ^{b)}	No	Alive without 3 rd relapse after salvage allo-HSCT
12	M	35	Low	14.9	ATO	CCR2	ATO 25 days 3 cycles	6 cycles	20.2	Yes ^{b)}	No	Alive without 3 rd relapse after salvage allo-HSCT
13	M	37	High	49.6	ATO	CCR2	ATO 25 days 2 cycles	8 cycles	55.7	No	No	Alive without 2 nd relapse
14	M	46	High	14.1	ATO	CMR2	ATO 25 days 2 cycles	None	8.3	Yes ^{b)}	Yes	Alive with 3 rd relapse after salvage allo-HSCT
15	M	22	High	6.5	ATO	CHR2	ATO 25 days 2 cycles	None	6.3	Yes	No	Expired due to infectious complications after 2 nd relapse
16	M	46	High	12.5	ATO	CMR	ATO 25 days 2 cycles	8 cycles	8.3	Yes ^{b)}	No	Alive without 3 rd relapse after salvage allo-HSCT
17	F	29	High	34.3	ATO+ATRA	CCR	ATO 10 days 5 cycles LDARA 2 cycles	None	110.3	No	No	Alive without 2 nd relapse
18	F	62	High	9.4	ATO	CCR	ATO 25 days 2 cycles	None	11.9	Yes	No	Expired due to infectious complications after 2 nd relapse
19	M	72	High	17.0	ATO	CCR	ATO 25 days 2 cycles	8 cycles	28.4	Yes	Yes	Expired due to disease progression after 3 rd relapse

^{a)}Maintenance consists of eight cycles of 6-mercaptopurine (50 mg/m²/day) plus ATRA per our hospital protocol. ^{b)}Five patients received allogeneic HSCT as salvage therapy after 2nd relapse of APL. The other two patients who received allogeneic HSCT relapsed after autologous HSCT. Abbreviations: ATO, arsenic trioxide; ATRA, all-trans-retinoic acid; CHR, complete hematologic response; CMR, complete molecular response; HSCT, hematopoietic stem cell transplantation; IDV, idarubicin; LDARA, low-dose cytarabine; MTZ, mitoxantrone.